Literature DB >> 17805236

Parathyroid hormone fragments inhibit active hormone and hypocalcemia-induced 1,25(OH)2D synthesis.

M Usatii1, L Rousseau, C Demers, J-L Petit, J-H Brossard, M Gascon-Barré, J R Lavigne, R J Zahradnik, E F Nemeth, P D'Amour.   

Abstract

Carboxyl (C)-terminal fragments of parathyroid hormone (PTH) oppose the calcemic, phosphaturic, and bone-resorbing effects of active hormone. To study the action of these fragments on 1,25(OH)(2)D (1,25-dihydroxyvitamin D) synthesis, we infused parathyroidectomized rats with human or rat active 1-34 or 1-84 PTH at doses selected to produce similar calcemic responses. Human active PTH influenced neither phosphate nor 1,25(OH)(2)D concentrations. However, active 1-34 rat PTH decreased phosphate to the same level as vehicle-treated rats and increased 1,25(OH)(2)D to very high levels, whereas active 1-84 PTH decreased phosphate but maintained 1,25(OH)(2)D. As the latter effect could have been due to C-terminal fragment generation during its metabolic breakdown, we infused a mixture of rat C-terminal fragments alone or with rat 1-34. The C-terminal fragments decreased 1,25(OH)(2)D and prevented hypocalcemic-induced 1,25(OH)(2)D synthesis. When infused with active rat 1-34, they lowered the 1,25(OH)(2)D level to that seen with intact rat 1-84. The C-terminal fragments did not influence either basal or rat 1-34- or 1-84-induced CYP27B1 mRNA levels, suggesting that their inhibitory effects on 1,25(OH)(2)D synthesis appears to be post-transcriptional.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17805236     DOI: 10.1038/sj.ki.5002532

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  15 in total

1.  Human parathyroid hormone is secreted primarily into the bloodstream after rat parotid gland gene transfer.

Authors:  J Adriaansen; P Perez; C Zheng; M T Collins; B J Baum
Journal:  Hum Gene Ther       Date:  2011-01-03       Impact factor: 5.695

Review 2.  Lessons from a second- and third-generation parathyroid hormone assays in renal failure patients.

Authors:  P D'Amour
Journal:  J Endocrinol Invest       Date:  2008-05       Impact factor: 4.256

3.  Vitamin D and the kidney.

Authors:  Kevin J Martin; Esther A González
Journal:  Mo Med       Date:  2012 Mar-Apr

4.  Amino terminal cleavage of PTH(1-84) to PTH(7-84) is regulated by serum calcium concentration via calcium-sensing receptor in hemodialysis patients.

Authors:  Masao Koshikawa; Kensuke Nishiguchi; Soshi Yorifuji; Keiji Shimazu; Koji Takaori; Keita Mori; Eriko Eguchi; Kikuo Okada; Atsuo Tanaka; Takashi Kuwahara
Journal:  Clin Exp Nephrol       Date:  2010-02-04       Impact factor: 2.801

5.  Vitamin D and kidney disease.

Authors:  Wisam Al-Badr; Kevin J Martin
Journal:  Clin J Am Soc Nephrol       Date:  2008-05-01       Impact factor: 8.237

6.  Production and sorting of transgenic, modified human parathyroid hormone in vivo in rat salivary glands.

Authors:  Janik Adriaansen; Changyu Zheng; Paola Perez; Bruce J Baum
Journal:  Biochem Biophys Res Commun       Date:  2009-11-26       Impact factor: 3.575

7.  Analysis of CYP27B1, encoding 25-hydroxyvitamin D-1alpha-hydroxylase, as a candidate tumor suppressor gene in primary and severe secondary/tertiary hyperparathyroidism.

Authors:  Kelly Lauter; Andrew Arnold
Journal:  J Bone Miner Res       Date:  2009-01       Impact factor: 6.741

8.  Influence of Secondary Hyperparathyroidism Induced by Low Dietary Calcium, Vitamin D Deficiency, and Renal Failure on Circulating Rat PTH Molecular Forms.

Authors:  Pierre D'Amour; Louise Rousseau; Stephen Hornyak; Zan Yang; Tom Cantor
Journal:  Int J Endocrinol       Date:  2011-06-22       Impact factor: 3.257

Review 9.  Vitamin D and chronic kidney disease.

Authors:  Chang Seong Kim; Soo Wan Kim
Journal:  Korean J Intern Med       Date:  2014-06-27       Impact factor: 2.884

10.  Vitamin D supplementation in pre-dialysis chronic kidney disease: A systematic review.

Authors:  Jessica Alvarez; Haimanot Wasse; Vin Tangpricha
Journal:  Dermatoendocrinol       Date:  2012-04-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.